Taysha Gene Therapies, Inc. (TSHA)Healthcare | Biotechnology | Dallas, United States | NasdaqGS
6.08 USD
-0.39
(-5.960%) ⇩
(April 21, 2026, 12:32 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 10:52 p.m. EDT
Taysha (TSHA) is displaying classic 'hockey stick' accumulation dynamics ahead of a pivotal clinical trial for its Rett syndrome therapy. Despite a fundamental value trap with negative earnings and high PE ratios, the extreme upside skew in call Open Interest versus negligible put activity signals that smart money is buying the dip, expecting the next FDA update to trigger a breakout from its consolidation range. The recent price action (up ~20% in two weeks) confirms the bottom is in and speculation is shifting back toward risk-on sentiment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.055876 |
| MSTL | 0.055953 |
| AutoTheta | 0.069118 |
| AutoARIMA | 0.071492 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 8.40 |
| Ljung-Box p | 0.065 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 8.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 28.405 |
| Revenue per Share | 0.031 |
| Market Cap | 1,745,164,544 |
| Forward P/E | -14.91 |
| Beta | 1.08 |
| Website | https://www.tayshagtx.com |
As of April 18, 2026, 10:52 p.m. EDT: Options activity shows a distinct bullish divergence despite low underlying volume. Call Open Interest (OI) is heavily concentrated at near-money and slightly out-of-money strikes (6.0, 7.5, 10.0), particularly in the April and June expirations, suggesting traders are positioning for an immediate pop. Interestingly, while implied volatility remains low (~1.0-2.0%), the call 'distance to strike' indicates a significant upside preference compared to puts. Put activity is minimal, with OI concentrated only in deep OTM range (0.5, 2.5, 4.0) for the near term, indicating a lack of hedging or fear relative to the call positioning. The high ATM volume at strike 10.0 for June expirations specifically targets upside momentum if the company hits its Q2 therapeutic milestones.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.6292136 |
| Address1 | 3,000 Pegasus Park Drive |
| Address2 | Suite 1430 |
| All Time High | 33.35 |
| All Time Low | 0.5 |
| Ask | 7.79 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 3,374,910 |
| Average Daily Volume3 Month | 2,816,829 |
| Average Volume | 2,816,829 |
| Average Volume10Days | 3,374,910 |
| Beta | 1.079 |
| Bid | 4.55 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.866 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.075 |
| Current Ratio | 12.227 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.45 |
| Day Low | 6.065 |
| Debt To Equity | 28.405 |
| Display Name | Taysha Gene Therapies |
| Earnings Call Timestamp End | 1,773,923,400 |
| Earnings Call Timestamp Start | 1,773,923,400 |
| Earnings Timestamp | 1,773,923,400 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -109,353,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.688 |
| Enterprise To Revenue | 164.345 |
| Enterprise Value | 1,606,139,520 |
| Eps Current Year | -0.384 |
| Eps Forward | -0.4075 |
| Eps Trailing Twelve Months | -0.34 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.6709 |
| Fifty Day Average Change | 1.4041 |
| Fifty Day Average Change Percent | 0.30060586 |
| Fifty Two Week Change Percent | 262.92136 |
| Fifty Two Week High | 6.7 |
| Fifty Two Week High Change | -0.625 |
| Fifty Two Week High Change Percent | -0.093283586 |
| Fifty Two Week Low | 1.46 |
| Fifty Two Week Low Change | 4.615 |
| Fifty Two Week Low Change Percent | 3.1609588 |
| Fifty Two Week Range | 1.46 - 6.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,600,954,200,000 |
| Float Shares | 198,293,784 |
| Forward Eps | -0.4075 |
| Forward P E | -14.907975 |
| Free Cashflow | -56,697,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 9,773,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10663 |
| Held Percent Institutions | 0.96156 |
| Implied Shares Outstanding | 287,269,886 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-09-24 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. |
| Long Name | Taysha Gene Therapies, Inc. |
| Market | us_market |
| Market Cap | 1,745,164,544 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_665948579 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -108,995,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,852,890,758 |
| Number Of Analyst Opinions | 14 |
| Open | 6.45 |
| Operating Cashflow | -93,090,000 |
| Operating Margins | -5.15953 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 214 612 0000 |
| Previous Close | 6.46 |
| Price Eps Current Year | -15.820312 |
| Price Hint | 2 |
| Price To Book | 7.0150113 |
| Price To Sales Trailing12 Months | 178.56999 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.043 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.21429 |
| Region | US |
| Regular Market Change | -0.38500023 |
| Regular Market Change Percent | -5.959756 |
| Regular Market Day High | 6.45 |
| Regular Market Day Low | 6.065 |
| Regular Market Day Range | 6.065 - 6.45 |
| Regular Market Open | 6.45 |
| Regular Market Previous Close | 6.46 |
| Regular Market Price | 6.075 |
| Regular Market Time | 1,776,789,172 |
| Regular Market Volume | 883,194 |
| Return On Assets | -0.27422002 |
| Return On Equity | -0.68451 |
| Revenue Growth | 1.713 |
| Revenue Per Share | 0.031 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 287,269,885 |
| Shares Percent Shares Out | 0.1472 |
| Shares Short | 42,272,193 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 49,687,347 |
| Short Name | Taysha Gene Therapies, Inc. |
| Short Percent Of Float | 0.16350001 |
| Short Ratio | 13.54 |
| Source Interval | 15 |
| State | TX |
| Symbol | TSHA |
| Target High Price | 19.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 11.57143 |
| Target Median Price | 11.5 |
| Total Cash | 319,767,008 |
| Total Cash Per Share | 1.113 |
| Total Debt | 70,143,000 |
| Total Revenue | 9,773,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.18195 |
| Two Hundred Day Average Change | 1.8930497 |
| Two Hundred Day Average Change Percent | 0.45267153 |
| Type Disp | Equity |
| Volume | 883,194 |
| Website | https://www.tayshagtx.com |
| Zip | 75,247 |